124 related articles for article (PubMed ID: 35405680)
1. Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma.
Kojima Y; Shimoi T; Seo T; Yazaki S; Okuya T; Ohtake Y; Okuma HS; Shimomura A; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Tamura K; Yoshida A; Iwata S; Kobayashi E; Kawai A; Fujiwara Y; Yonemori K
Oncology; 2022; 100(7):370-375. PubMed ID: 35405680
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen.
Salah S; Yaser S; Salem A; Al Mousa A; Abu Sheikha A; Sultan I
Med Oncol; 2013; 30(3):639. PubMed ID: 23780657
[TBL] [Abstract][Full Text] [Related]
4. Systemic Treatment for Adults with Synovial Sarcoma.
Desar IME; Fleuren EDG; van der Graaf WTA
Curr Treat Options Oncol; 2018 Mar; 19(2):13. PubMed ID: 29516254
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience.
Ates O; Aksoy S; Yeter H; Sunar V; Kertmen N; Dizdar O; Turker A; Kars A
Indian J Cancer; 2017; 54(1):321-325. PubMed ID: 29199714
[TBL] [Abstract][Full Text] [Related]
6. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
[TBL] [Abstract][Full Text] [Related]
7. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma.
Pender A; Davis EJ; Chauhan D; Messiou C; Al-Muderis O; Thway K; Fisher C; Zaidi S; Miah A; Judson I; van der Graaf W; Keedy VL; Benson C; Jones RL
Med Oncol; 2018 Aug; 35(10):131. PubMed ID: 30128716
[TBL] [Abstract][Full Text] [Related]
8. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).
Moreau-Bachelard C; Campion L; Toulmonde M; Le Cesne A; Brahmi M; Italiano A; Mir O; Piperno-Neumann S; Laurence V; Firmin N; Penel N; Duffaud F; Chevreau C; Bertucci F; Narciso B; Dubray-Longeras P; Delcambre C; Saada-Bouzid E; Boudou-Rouquette P; Soulie P; Perrin C; Blay JY; Bompas E
ESMO Open; 2022 Apr; 7(2):100402. PubMed ID: 35202953
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital.
Spurrell EL; Fisher C; Thomas JM; Judson IR
Ann Oncol; 2005 Mar; 16(3):437-44. PubMed ID: 15653701
[TBL] [Abstract][Full Text] [Related]
10. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
11. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
12. A case of renal synovial sarcoma treated with adjuvant ifosfamide and doxorubicin.
Ozkan EE; Mertsoylu H; Ozardali HI
Intern Med; 2011; 50(15):1575-80. PubMed ID: 21804284
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
[TBL] [Abstract][Full Text] [Related]
15. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.
Rosen G; Forscher C; Lowenbraun S; Eilber F; Eckardt J; Holmes C; Fu YS
Cancer; 1994 May; 73(10):2506-11. PubMed ID: 8174046
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond).
Carroll C; Patel N; Gunsoy NB; Stirnadel-Farrant HA; Pokras S
Future Oncol; 2022 Oct; 18(32):3651-3665. PubMed ID: 36399116
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.
Sanfilippo R; Dileo P; Blay JY; Constantinidou A; Le Cesne A; Benson C; Vizzini L; Contu M; Baldi GG; Dei Tos AP; Casali PG
Anticancer Drugs; 2015 Jul; 26(6):678-81. PubMed ID: 25763543
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
